Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Iptacopan hydrochloride by Novartis for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis): Likelihood of Approval
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Membranoproliferative Glomerulonephritis (Mesangiocapillary Glomerulonephritis). According to...
Iptacopan hydrochloride by Novartis for Myasthenia Gravis: Likelihood of Approval
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase...
Iptacopan hydrochloride by Novartis for Proteinuria: Likelihood of Approval
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Proteinuria. According to GlobalData, Phase III...
Iptacopan hydrochloride by Novartis for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener's Granulomatosis). According...
Iptacopan hydrochloride by Novartis for Microscopic Polyangiitis (MPA): Likelihood of Approval
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Microscopic Polyangiitis (MPA). According to GlobalData,...
Iptacopan hydrochloride by Novartis for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)....
Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. According to GlobalData, Phase III...